Fig. 3From: First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumorsTumor response. The waterfall plot (A, C, E) of the best overall responses with respect to the tumor size and the swimmer plot (B, D, F) of time to tumor response in non-small-cell lung cancer (NSCLC) patients (A, B), nasopharyngeal carcinoma (NPC) patients (C, D), and cervical cancer (CC) patients (E, F)Back to article page